ESC 2024: CATHEDRAL-HF trial results have the potential to reduce polypharmacy
Dr. Deborah Belfort presented CATHEDRAL-HF trial findings at ESC, showing discontinuation of HF treatment while maintaining carvedilol could be safe in HF with improved EF. Key opinion leaders highlighted suboptimal medication doses in chronic HF patients, and HF is a lifelong condition with various acute causes.
Highlighted Terms
Related News
ESC 2024: CATHEDRAL-HF trial results have the potential to reduce polypharmacy
Dr. Deborah Belfort presented CATHEDRAL-HF trial findings at ESC, showing discontinuation of HF treatment while maintaining carvedilol could be safe in HF with improved EF. Key opinion leaders highlighted suboptimal medication doses in chronic HF patients, and HF is a lifelong condition with various acute causes.